Phosphoprotein abundance changes in hypertensive cardiac remodeling

Journal of Proteomics

Volumn 77, Issue , 2012, Pages 1-13

  Kotlo, Kumar ^a,b   Johnson, Keven R ^a   Grillon, Jean M ^a   Geenen, David L ^a   deTombe, Pieter ^c   Danziger, Robert S ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Research and Development   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

2D DIGE; Dahl rats; Heart failure; Hypertrophy; Phospho profiling; Pressure overload

Indexed keywords

2 OXOISOVALERATE DEHYDROGENASE (LIPOAMIDE); ALPHA TROPOMYOSIN; BETA TUBULIN; INITIATION FACTOR 1A; MITOCHONDRIAL CREATINE KINASE; MITOCHONDRIAL PROTEIN; MYOSIN LIGHT CHAIN 2; PHOSPHATASE; PHOSPHOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEASOME; PROTEIN CAPZ; PYRUVATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HEART FAILURE; HEART LEFT VENTRICLE OVERLOAD; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; MYOFILAMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; CARDIOMEGALY; HEART FAILURE; HYPERTENSION; MUSCLE PROTEINS; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHOPROTEINS; RATS; RATS, INBRED SHR; RATS, WISTAR; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VENTRICULAR REMODELING;

EUKARYOTA; RATTUS;

EID: 84870392984     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.05.041     Document Type: Article

References (88)

1. Cantley L.C. The phosphoinositide 3-kinase pathway. Science May 31 2002, 296(5573):1655-1657.
2. Shiojima I., Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev Dec 15 2006, 20(24):3347-3365.
3. Shioi T., Kang P.M., Douglas P.S., Hampe J., Yballe C.M., Lawitts J., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J Jun 1 2000, 19(11):2537-2548.
4. Matsui T., Li L., Wu J.C., Cook S.A., Nagoshi T., Picard M.H., et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem Jun 21 2002, 277(25):22896-22901.
5. Blankesteijn W.M., van de Schans V.A., ter Horst P., Smits J.F. The Wnt/frizzled/GSK-3beta pathway: a novel therapeutic target for cardiac hypertrophy. Trends Pharmacol Sci Apr 2008, 29(4):175-180.
6. Trivedi C.M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med Mar 2007, 13(3):324-331.
7. Li J.M., Brooks G. Differential protein expression and subcellular distribution of TGFbeta1, beta2 and beta3 in cardiomyocytes during pressure overload-induced hypertrophy. J Mol Cell Cardiol Aug 1997, 29(8):2213-2224.
8. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990, 6:597-641.
9. Ikeda Y., Hoshijima M., Chien K.R. Toward biologically targeted therapy of calcium cycling defects in heart failure. Physiology (Bethesda) Feb 2008, 23:6-16.
10. Hasenfuss G., Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol Aug 2002, 34(8):951-969.
11. Kirchhefer U., Schmitz W., Scholz H., Neumann J. Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc Res Apr 1999, 42(1):254-261.
12. Zhang T., Maier L.S., Dalton N.D., Miyamoto S., Ross J., Bers D.M., et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res May 2 2003, 92(8):912-919.
13. Lai N.C., Tang T., Gao M.H., Saito M., Takahashi T., Roth D.M., et al. Activation of cardiac adenylyl cyclase expression increases function of the failing ischemic heart in mice. J Am Coll Cardiol Apr 15 2008, 51(15):1490-1497.
14. Takahashi T., Tang T., Lai N.C., Roth D.M., Rebolledo B., Saito M., et al. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation Aug 1 2006, 114(5):388-396.
15. Fukuda N., Wu Y., Nair P., Granzier H.L. Phosphorylation of titin modulates passive stiffness of cardiac muscle in a titin isoform-dependent manner. J Gen Physiol Mar 2005, 125(3):257-271.
16. Frantz S., Behr T., Hu K., Fraccarollo D., Strotmann J., Goldberg E., et al. Role of p38 mitogen-activated protein kinase in cardiac remodelling. Br J Pharmacol Jan 2007, 150(2):130-135.
17. Moschella P.C., Rao V.U., McDermott P.J., Kuppuswamy D. Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKCepsilon and PKCdelta, in adult cardiac muscle cells. J Mol Cell Cardiol Dec 2007, 43(6):754-766.
18. Lee T.M., Lin M.S., Tsai C.H., Chang N.C. Effects of pravastatin on ventricular remodeling by activation of myocardial KATP channels in infarcted rats: role of 70-kDa S6 kinase. Basic Res Cardiol Mar 2007, 102(2):171-182.
19. Sanada S., Node K., Asanuma H., Ogita H., Takashima S., Minamino T., et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase. J Am Coll Cardiol Sep 4 2002, 40(5):991-997.
20. Muslin A.J. Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc Med Aug 2005, 15(6):225-229.
21. Pantos C., Xinaris C., Mourouzis I., Malliopoulou V., Kardami E., Cokkinos D.V. Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: potential therapeutic implications in reversing cardiac remodeling?. Mol Cell Biochem Mar 2007, 297(1-2):65-72.
22. Beckles D.L., Mascareno E., Siddiqui M.A. Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul Pharmacol Dec 2006, 45(6):350-357.
23. Muraski J.A., Rota M., Misao Y., Fransioli J., Cottage C., Gude N., et al. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med Dec 2007, 13(12):1467-1475.
24. Grote-Wessels S., Baba H.A., Boknik P., El-Armouche A., Fabritz L., Gillmann H.J., et al. Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload. Cardiovasc Res 2008, 79(3):464-471.
25. Gupta R.C., Mishra S., Rastogi S., Imai M., Habib O., Sabbah H.N. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol Dec 2003, 285(6):H2373-H2381.
26. Gupta R.C., Mishra S., Yang X.P., Sabbah H.N. Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats. Mol Cell Biochem Jan 2005, 269(1-2):49-57.
27. Pathak A., del Monte F., Zhao W., Schultz J.E., Lorenz J.N., Bodi I., et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res Apr 15 2005, 96(7):756-766.
28. van Oort R.J., van Rooji E., Bourajjaj M., Schimmel J., Jansen M.A., van der Nagel R., et al. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. Circulation Jul 25 2006, 114(4):298-308.
29. Sakata Y., Masuyama T., Yamamoto K., Nishikawa N., Yamamoto H., Kondo H., et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation Oct 31 2000, 102(18):2269-2275.
30. Dousa T.P. Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int Jan 1999, 55(1):29-62.
31. Heineke J., Ruetten H., Willenbockel C., Gross S.C., Naguib M., Schaefer A., et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci U S A Feb 1 2005, 102(5):1655-1660.
32. Napolitano R., Vittone L., Mundina C., Chiappe de Cingolani G., Mattiazzi A. Phosphorylation of phospholamban in the intact heart. A study on the physiological role of the Ca(2+)-calmodulin-dependent protein kinase system. J Mol Cell Cardiol Apr 1992, 24(4):387-396.
33. Movsesian M.A., Colyer J., Wang J.H., Krall J. Phospholamban-mediated stimulation of Ca2+ uptake in sarcoplasmic reticulum from normal and failing hearts. J Clin Invest May 1990, 85(5):1698-1702.
34. Vittone L., Mundina-Weilenmann C., Mattiazzi A. Phospholamban phosphorylation by CaMKII under pathophysiological conditions. Front Biosci 2008, 13:5988-6005.
35. Altschuld R.A., Starling R.C., Hamlin R.L., Billman G.E., Hensley J., Castillo L., et al. Response of failing canine and human heart cells to beta 2-adrenergic stimulation. Circulation Sep 15 1995, 92(6):1612-1618.
36. Schwinger R.H., Bolck B., Munch G., Brixius K., Muller-Ehmsen J., Erdmann E. cAMP-dependent protein kinase A-stimulated sarcoplasmic reticulum function in heart failure. Ann N Y Acad Sci Sep 16 1998, 853:240-250. (240-50).
37. Desantiago J., Ai X., Islam M., Acuna G., Ziolo M.T., Bers D.M., et al. Arrhythmogenic Effects of {beta}2-Adrenergic Stimulation in the Failing Heart Are Attributable to Enhanced Sarcoplasmic Reticulum Ca Load. Circ Res 2008, 102(11):1389-1397.
38. Akar F.G., Spragg D.D., Tunin R.S., Kass D.A., Tomaselli G.F. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res Oct 1 2004, 95(7):717-725.
39. Ai X., Pogwizd S.M. Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A. Circ Res Jan 7 2005, 96(1):54-63.
40. Gill R.M., Braz J.C., Jin N., Etgen G.J., Shen W. Restoration of impaired endothelium-dependent coronary vasodilation in failing heart: role of eNOS phosphorylation and CGMP/cGK-I signaling. Am J Physiol Heart Circ Physiol Jun 2007, 292(6):H2782-H2790.
41. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell Aug 23 2002, 110(4):479-488.
42. Vega R.B., Harrison B.C., Meadows E., Roberts C.R., Papst P.J., Olson E.N., et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol Oct 2004, 24(19):8374-8385.
43. Takeishi Y., Huang Q., Abe J., Che W., Lee J.D., Kawakatsu H., et al. Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy. Cardiovasc Res Jan 2002, 53(1):131-137.
44. Muller F.U., Boknik P., Knapp J., Linck B., Luss H., Neumann J., et al. Activation and inactivation of cAMP-response element-mediated gene transcription in cardiac myocytes. Cardiovasc Res Oct 2001, 52(1):95-102.
45. Muller F.U., Boknik P., Knapp J., Neumann J., Vahlensieck U., Oetjen E., et al. Identification and expression of a novel isoform of cAMP response element modulator in the human heart. FASEB J Sep 1998, 12(12):1191-1199.
46. Muller F.U., Boknik P., Horst A., Knapp J., Linck B., Schmitz W., et al. cAMP response element binding protein is expressed and phosphorylated in the human heart. Circulation Oct 15 1995, 92(8):2041-2043.
47. Matus M., Lewin G., Stumpel F., Buchwalow I.B., Schneider M.D., Schutz G., et al. Cardiomyocyte-specific inactivation of transcription factor CREB in mice. FASEB J Jun 2007, 21(8):1884-1892.
48. Lehnart S.E., Wehrens X.H., Reiken S., Warrier S., Belevych A.E., Harvey R.D., et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell Oct 7 2005, 123(1):25-35.
49. Liao Y., Zhao H., Ogai A., Kato H., Asakura M., Kim J., et al. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res Feb 2008, 31(2):335-344.
50. Skurk C., Izumiya Y., Maatz H., Razeghi P., Shiojima I., Sandri M., et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem May 27 2005, 280(21):20814-20823.
51. Vahtola E., Louhelainen M., Merasto S., Martonen E., Penttinen S., Aahos I., et al. Forkhead class O transcription factor 3a activation and Sirtuin1 overexpression in the hypertrophied myocardium of the diabetic Goto-Kakizaki rat. J Hypertens Feb 2008, 26(2):334-344.
52. Obreztchikova M., Elouardighi H., Ho M., Wilson B.A., Gertsberg Z., Steinberg S.F. Distinct signaling functions for Shc isoforms in the heart. J Biol Chem Jul 21 2006, 281(29):20197-20204.
53. Venkatakrishnan C.D., Tewari A.K., Moldovan L., Cardounel A.J., Zweier J.L., Kuppusamy P., et al. Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27. Am J Physiol Heart Circ Physiol Dec 2006, 291(6):H2680-H2691.
54. Tuxworth W.J., Saghir A.N., Spruill L.S., Menick D.R., McDermott P.J. Regulation of protein synthesis by eIF4E phosphorylation in adult cardiocytes: the consequence of secondary structure in the 5'-untranslated region of mRNA. Biochem J Feb 15 2004, 378(Pt 1):73-82.
55. Belin R.J., Sumandea M.P., Allen E.J., Schoenfelt K., Wang H., Solaro R.J., et al. Augmented protein kinase C-alpha-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure. Circ Res Jul 2007, 101(2):195-204.
56. van der Velden J., Papp Z., Boontje N.M., Zaremba R., de Jong J.W., Janssen P.M., et al. Myosin light chain composition in non-failing donor and end-stage failing human ventricular myocardium. Adv Exp Med Biol 2003, 538:3-15. (3-15).
57. Milting H., Scholz C., Arusoglu L., Freitag M., Cebulla R., Jaquet K., et al. Selective upregulation of beta1-adrenergic receptors and dephosphorylation of troponin I in end-stage heart failure patients supported by ventricular assist devices. J Mol Cell Cardiol Sep 2006, 41(3):441-450.
58. Pott C., Willkomm L., Grafweg S., Bolck B., Dorn G.W., Schwinger R.H., et al. Reduced troponin I phosphorylation and increased Ca(2+)-dependent ATP-consumption in triton X-skinned fiber preparations from Galphaq overexpressor mice. Mol Cell Biochem 2008, 314(1-2):133-141.
59. Yuan C., Guo Y., Ravi R., Przyklenk K., Shilkofski N., Diez R., et al. Myosin binding protein C is differentially phosphorylated upon myocardial stunning in canine and rat hearts- evidence for novel phosphorylation sites. Proteomics Jul 2006, 6(14):4176-4186.
60. Lamberts R.R., Hamdani N., Soekhoe T.W., Boontje N.M., Zaremba R., Walker L.A., et al. Frequency-dependent myofilament Ca2+ desensitization in failing rat myocardium. J Physiol Jul 15 2007, 582(Pt 2):695-709.
61. Belin R.J., Sumandea M.P., Kobayashi T., Walker L.A., Rundell V.L., Urboniene D., et al. Left ventricular myofilament dysfunction in rat experimental hypertrophy and congestive heart failure. Am J Physiol Heart Circ Physiol Nov 2006, 291(5):H2344-H2353.
62. Vahebi S., Ota A., Li M., Warren C.M., de Tombe P.P., Wang Y., et al. p38-MAPK induced dephosphorylation of alpha-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity. Circ Res Feb 16 2007, 100(3):408-415.
63. Sack M.N., Rader T.A., Park S., Bastin J., McCune S.A., Kelly D.P. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation Dec 1 1996, 94(11):2837-2842.
64. Inagaki K., Iwanaga Y., Sarai N., Onozawa Y., Takenaka H., Mochly-Rosen D., et al. Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta. J Mol Cell Cardiol Oct 2002, 34(10):1377-1385.
65. Li Y.F., Wang X. The role of the proteasome in heart disease. Biochim Biophys Acta Feb 2011, 1809(2):141-149.
66. Asai M., Tsukamoto O., Minamino T., Asanuma H., Fujita M., Asano Y., et al. PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts. J Mol Cell Cardiol Apr 2009, 46(4):452-462.
67. Banfi C., Brioschi M., Wait R., Begum S., Gianazza E., Fratto P., et al. Proteomic analysis of membrane microdomains derived from both failing and non-failing human hearts. Proteomics Mar 2006, 6(6):1976-1988.
68. Qanud K., Mamdani M., Pepe M., Khairallah R.J., Gravel J., Lei B., et al. Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure. Am J Physiol Heart Circ Physiol Nov 2008, 295(5):H2098-H2105.
69. Lin G., Brownsey R.W., MacLeod K.M. Regulation of mitochondrial aconitase by phosphorylation in diabetic rat heart. Cell Mol Life Sci Mar 2009, 66(5):919-932.
70. Nicolaou P., Hajjar R.J., Kranias E.G. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol Sep 2009, 47(3):365-371.
71. Bruchert N., Mavila N., Boknik P., Baba H.A., Fabritz L., Gergs U., et al. Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality. Am J Physiol Heart Circ Physiol Oct 2008, 295(4):H1539-H1546.
72. El-Armouche A., Pamminger T., Ditz D., Zolk O., Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res Jan 1 2004, 61(1):87-93.
73. Lowes B.D., Gilbert E.M., Abraham W.T., Minobe W.A., Larrabee P., Ferguson D., et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med May 2 2002, 346(18):1357-1365.
74. Dinischiotu A., Beullens M., Stalmans W., Bollen M. Identification of sds22 as an inhibitory subunit of protein phosphatase-1 in rat liver nuclei. FEBS Lett Feb 3 1997, 402(2-3):141-144.
75. Eckhardt K., Troger J., Reissmann J., Katschinski D.M., Wagner K.F., Stengel P., et al. Male germ cell expression of the PAS domain kinase PASKIN and its novel target eukaryotic translation elongation factor eEF1A1. Cell Physiol Biochem 2007, 20(1-4):227-240.
76. Kittleson M.M., Minhas K.M., Irizarry R.A., Ye S.Q., Edness G., Breton E., et al. Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genomics May 11 2005, 21(3):299-307.
77. Heling A., Zimmermann R., Kostin S., Maeno Y., Hein S., Devaux B., et al. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res Apr 28 2000, 86(8):846-853.
78. Eyers C.E., McNeill H., Knebel A., Morrice N., Arthur S.J., Cuenda A., et al. The phosphorylation of CapZ-interacting protein (CapZIP) by stress-activated protein kinases triggers its dissociation from CapZ. Biochem J Jul 1 2005, 389(Pt 1):127-135.
79. Janssens V., Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J Feb 1 2001, 353(Pt 3):417-439.
80. Larsen K.O., Lygren B., Sjaastad I., Krobert K.A., Arnkvaern K., Florholmen G., et al. Diastolic dysfunction in alveolar hypoxia: a role for interleukin-18-mediated increase in protein phosphatase 2A. Cardiovasc Res Oct 1 2008, 80(1):47-54.
81. Terentyev D., Belevych A.E., Terentyeva R., Martin M.M., Malana G.E., Kuhn D.E., et al. miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res Feb 27 2009, 104(4):514-521.
82. Cheng G., Takahashi M., Shunmugavel A., Wallenborn J.G., Paoli-Roach A.A., Gergs U., et al. Basis for MAP4 dephosphorylation-related microtubule network densification in pressure overload cardiac hypertrophy. J Biol Chem Dec 3 2010, 285(49):38125-38140.
83. Neviere R., Hassoun S.M., Decoster B., Bouazza Y., Montaigne D., Marechal X., et al. Caspase-dependent protein phosphatase 2A activation contributes to endotoxin-induced cardiomyocyte contractile dysfunction. Crit Care Med Oct 2010, 38(10):2031-2036.
84. De Souza A.I., Cardin S., Wait R., Chung Y.L., Vijayakumar M., Maguy A., et al. Proteomic and metabolomic analysis of atrial profibrillatory remodelling in congestive heart failure. J Mol Cell Cardiol Nov 2010, 49(5):851-863.
85. Piao L., Fang Y.H., Cadete V.J., Wietholt C., Urboniene D., Toth P.T., et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med Jan 2010, 88(1):47-60.
86. Westermann S., Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol Dec 2003, 4(12):938-947.
87. Streicher J.M., Ren S., Herschman H., Wang Y. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res Apr 30 2010, 106(8):1434-1443.
88. Lemke L.E., Bloem L.J., Fouts R., Esterman M., Sandusky G., Vlahos C.J. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart. J Mol Cell Cardiol Aug 2001, 33(8):1527-1540.